# Octant Bio

> Synthetic-biology drug discovery using engineered human cell lines as disease reporters.

## Why it is interesting

Sri Kosuri's antedisciplinary biotech — a16z led the Series A (2020) for GPCR drug maps built from programmable cell reporters; raised $115M+ total.

## Profile

- **Stage:** series-b
- **Status:** private
- **Industries:** biotech-life-sciences, healthtech
- **Coverage:** full
- **Last updated:** 2026-07-24

## Key facts

- Series A (May 2020): $30M led by a16z; 8VC participated (GenomeWeb, a16z)
- Series B (Apr 2022): additional financing; total raised ~$115M (Tracxn)
- Co-investors not in VCT directory: 8VC, Catalio Capital, SV Angel
- Co-investors: no additional institutional investors disclosed in public sources reviewed 2026-07-24

## Investors in our directory

- https://venturecapitaltracker.com/fund/andreessen-horowitz

## Related articles

- https://venturecapitaltracker.com/2026-a16z-hot-portfolio-companies

---
Source: https://venturecapitaltracker.com/startup/octant-bio